Literature DB >> 20184870

Urinary matrix metalloproteinase-8 and -9 activities in type 2 diabetic subjects: A marker of incipient diabetic nephropathy?

Nynke J van der Zijl1, Roeland Hanemaaijer, Maarten E Tushuizen, Roger K Schindhelm, Jeannette Boerop, Cees Rustemeijer, Henk J Bilo, Jan H Verheijen, Michaela Diamant.   

Abstract

Matrix metalloproteinases (MMPs) may play a pathophysiological role in the development of diabetic nephropathy (DN). We hypothesized that urinary MMP activity in patients with type 2 diabetes mellitus (T2DM) is related to a decline in renal function. We determined MMP-2, -8 and -9 activity in 24-h urine collections in relation to risk factors for DN in T2DM patients with (UA, n=27) and without albuminuria (NA, n=48) and controls (CO, n=28). MMP-8 and -9 levels were highest in UA patients (P<0.01). Of UA patients, 93% had at least one MMP increased, compared to 78% of NA patients and 46% of CO (P=0.001). Age, diabetes duration, BMI, systolic blood pressure, fasting plasma glucose, HbA1c and renal function were determinants of MMP-8 and -9 (P<0.05). In summary, MMP-8 and -9 are highest in T2DM UA patients. MMP-9, showed the strongest associations with clinical parameters related to DN. 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20184870     DOI: 10.1016/j.clinbiochem.2010.02.006

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  18 in total

Review 1.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in chronic kidney disease and acute kidney injury: a systematic review of the literature.

Authors:  C L Sampieri; R A Orozco-Ortega
Journal:  Hippokratia       Date:  2018 Jul-Sep       Impact factor: 0.471

2.  Urinary matrix metalloproteinase activities: biomarkers for plaque angiogenesis and nephropathy in diabetes.

Authors:  Ian B McKittrick; Yolanda Bogaert; Kristen Nadeau; Janet Snell-Bergeon; Amber Hull; Tao Jiang; Xiaoxin Wang; Moshe Levi; Karen S Moulton
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-14

Review 3.  Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases.

Authors:  Aina He; Guo-Ping Shi
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 4.  Matrix metalloproteinases in kidney homeostasis and diseases.

Authors:  Roderick J Tan; Youhua Liu
Journal:  Am J Physiol Renal Physiol       Date:  2012-04-04

Review 5.  A glimpse of matrix metalloproteinases in diabetic nephropathy.

Authors:  X Xu; L Xiao; P Xiao; S Yang; G Chen; F Liu; Y S Kanwar; L Sun
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

Review 6.  Matrix metalloproteinase 14 modulates diabetes and Alzheimer's disease cross-talk: a meta-analysis.

Authors:  Jack Cheng; Hsin-Ping Liu; Cheng-Chun Lee; Mei-Ying Chen; Wei-Yong Lin; Fuu-Jen Tsai
Journal:  Neurol Sci       Date:  2017-11-04       Impact factor: 3.307

7.  Type 1 diabetes mellitus induces structural changes and molecular remodelling in the rat kidney.

Authors:  Raphael M Singh; Frank C Howarth; Ernest Adeghate; Keshore Bidasee; Jaipaul Singh; Tehreem Waqar
Journal:  Mol Cell Biochem       Date:  2018-02-23       Impact factor: 3.396

8.  Schizophrenia gene expression profile reverted to normal levels by antipsychotics.

Authors:  Benedicto Crespo-Facorro; Carlos Prieto; Jesus Sainz
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

9.  Urinary matrix metalloproteinase activity in diabetic kidney disease: a potential marker of disease progression.

Authors:  Nagi Altemtam; Meguid El Nahas; Tim Johnson
Journal:  Nephron Extra       Date:  2012-08-09

10.  Effects of reduced β2-glycoprotein I on the expression of aortic matrix metalloproteinases and tissue inhibitor matrix metalloproteinases in diabetic mice.

Authors:  Jun Xu; Penghua Wang; Tong Wang; Meijun Wang; Sisi Chen; Pei Yu; Demin Yu
Journal:  BMC Cardiovasc Disord       Date:  2014-09-10       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.